GlassScriptPhysician profile
Sharan Kaur Manhas
NPI 1689655797
$2,596.84
in general payments reported to CMS, 2019-2025
12 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2021: $1,009 · 2022: $337 · 2023: $500 · 2024: $124 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $500 · Food and Beverage: $418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $500.00 |
| Food and Beverage | $417.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $614.26 | 2021-2022 | |
| Bard Peripheral Vascular, INC. | $500.00 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $250.00 | 2021 | |
| Sk Life Science, INC. | $221.71 | 2022-2024 | Xcopri |
| Abbott Laboratories | $171.26 | 2025 | Infinity |
| Grifols USA, LLC | $134.15 | 2021 | |
| Greenwich Biosciences, INC. | $125.00 | 2021 | |
| Viz.Ai, INC. | $124.59 | 2021 | |
| Amgen INC. | $124.34 | 2019 | |
| Ucb, INC. | $122.71 | 2025 | Fintepla |
| Avanir Pharmaceuticals, INC. | $108.39 | 2019 | |
| Lilly USA, LLC | $100.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharan Manhas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.